Interim results of a first-in-human phase 1 dose-escalation trial of tak-102, a glypican-3 targeted armored chimeric antigen receptor tcell immunotherapy in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要